<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Manfredi F</submitter><funding>Academy of Finland</funding><funding>Associazione Italiana per la Ricerca sul Cancro</funding><funding>Italian Ministry of Health and Alliance Against Cancer (Ricerca Corrente</funding><funding>Italian Ministry of Education, University and Research</funding><pagination>eadg8014</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10691777</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(48)</volume><pubmed_abstract>To study and then harness the tumor-specific T cell dynamics after allogeneic hematopoietic stem cell transplant, we typed the frequency, phenotype, and function of lymphocytes directed against tumor-associated antigens (TAAs) in 39 consecutive transplanted patients, for 1 year after transplant. We showed that TAA-specific T cells circulated in 90% of patients but display a limited effector function associated to an exhaustion phenotype, particularly in the subgroup of patients deemed to relapse, where exhausted stem cell memory T cells accumulated. Accordingly, cancer-specific cytolytic functions were relevant only when the TAA-specific T cell receptors (TCRs) were transferred into healthy, genome-edited T cells. We then exploited trogocytosis and ligandome-on-chip technology to unveil the specificities of tumor-specific TCRs retrieved from the exhausted T cell pool. Overall, we showed that harnessing circulating TAA-specific and exhausted T cells allow to isolate TCRs against TAAs and previously not described acute myeloid leukemia antigens, potentially relevant for T cell-based cancer immunotherapy.</pubmed_abstract><journal>Science advances</journal><pubmed_title>Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR.</pubmed_title><pmcid>PMC10691777</pmcid><funding_grant_id>RCR-2019-23669115</funding_grant_id><funding_grant_id>PRIN 2017WC8499</funding_grant_id><funding_grant_id>309608 AND 325222</funding_grant_id><funding_grant_id>AIRC-IG 18458 AND AIRC 5 PER MILLE 22737</funding_grant_id><pubmed_authors>Manfredi F</pubmed_authors><pubmed_authors>Feola S</pubmed_authors><pubmed_authors>Balestrieri C</pubmed_authors><pubmed_authors>Cianciotti BC</pubmed_authors><pubmed_authors>Abbati D</pubmed_authors><pubmed_authors>Lehtio J</pubmed_authors><pubmed_authors>Cerullo V</pubmed_authors><pubmed_authors>Magnani Z</pubmed_authors><pubmed_authors>Ciceri F</pubmed_authors><pubmed_authors>Vago L</pubmed_authors><pubmed_authors>Bonini C</pubmed_authors><pubmed_authors>Tassi E</pubmed_authors><pubmed_authors>Sikanen TM</pubmed_authors><pubmed_authors>Potenza A</pubmed_authors><pubmed_authors>Punta M</pubmed_authors><pubmed_authors>Marzuttini F</pubmed_authors><pubmed_authors>Camisa B</pubmed_authors><pubmed_authors>Stasi L</pubmed_authors><pubmed_authors>Casucci M</pubmed_authors><pubmed_authors>Noviello M</pubmed_authors><pubmed_authors>Haapala MJ</pubmed_authors><pubmed_authors>Mastaglio S</pubmed_authors><pubmed_authors>Ruggiero E</pubmed_authors><pubmed_authors>Toffalori C</pubmed_authors><pubmed_authors>Branca RM</pubmed_authors><pubmed_authors>Tiziano E</pubmed_authors><pubmed_authors>Buonanno S</pubmed_authors><pubmed_authors>Lupo-Stanghellini MT</pubmed_authors></additional><is_claimable>false</is_claimable><name>Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR.</name><description>To study and then harness the tumor-specific T cell dynamics after allogeneic hematopoietic stem cell transplant, we typed the frequency, phenotype, and function of lymphocytes directed against tumor-associated antigens (TAAs) in 39 consecutive transplanted patients, for 1 year after transplant. We showed that TAA-specific T cells circulated in 90% of patients but display a limited effector function associated to an exhaustion phenotype, particularly in the subgroup of patients deemed to relapse, where exhausted stem cell memory T cells accumulated. Accordingly, cancer-specific cytolytic functions were relevant only when the TAA-specific T cell receptors (TCRs) were transferred into healthy, genome-edited T cells. We then exploited trogocytosis and ligandome-on-chip technology to unveil the specificities of tumor-specific TCRs retrieved from the exhausted T cell pool. Overall, we showed that harnessing circulating TAA-specific and exhausted T cells allow to isolate TCRs against TAAs and previously not described acute myeloid leukemia antigens, potentially relevant for T cell-based cancer immunotherapy.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Dec</publication><modification>2026-06-23T03:17:20.241Z</modification><creation>2025-02-19T01:18:09.597Z</creation></dates><accession>S-EPMC10691777</accession><cross_references><pubmed>38039364</pubmed><doi>10.1126/sciadv.adg8014</doi></cross_references></HashMap>